ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AGIX KraneShares Artificial Intelligence ETF

24.055
0.00 (0.00%)
Pre Market
Last Updated: 13:04:43
Delayed by 15 minutes
Name Symbol Market Type
KraneShares Artificial Intelligence ETF NASDAQ:AGIX NASDAQ Exchange Traded Fund
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 24.055 23.60 30.00 1 13:04:43

AtheroGenics to Report First Quarter 2008 Financial Results on April 24, 2008

17/04/2008 2:18pm

Marketwired


KraneShares Artificial I... (NASDAQ:AGIX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more KraneShares Artificial I... Charts.

ATLANTA, GA , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its first quarter 2008 financial results on Thursday, April 24, 2008 before the U.S. financial markets open.

Conference Call and Webcast Information

Company officials will discuss first quarter 2008 financial results via conference call and webcast on Thursday, April 24, 2008, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-689-8031 (international). To access the webcast, please visit the AtheroGenics Investor Relations website at www.atherogenics.com. A replay of the conference call will be accessible approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international), account number 286, conference ID number 281784. A replay of the webcast will be archived on the Company's website until July 25, 2008.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead product candidate, AGI-1067, is a novel antioxidant and anti-inflammatory agent that is currently being evaluated in a Phase III registration study called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) as an oral treatment for Type 2 diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

CONTACTS: AtheroGenics, Inc. Donna L. Glasky Corporate Communications 678-336-2517 Email Contact Media Inquiries Jayme Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770 Email Contact Investor Inquiries Lilian Stern Stern Investor Relations, Inc. 212-362-1200 Email Contact

1 Year KraneShares Artificial I... Chart

1 Year KraneShares Artificial I... Chart

1 Month KraneShares Artificial I... Chart

1 Month KraneShares Artificial I... Chart

Your Recent History

Delayed Upgrade Clock